HERZLIYA, Israel, July 16, 2014 /PRNewswire/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the
"Company"), a clinical-stage biopharmaceutical company focused on
the acquisition, development and commercialization of
pharmaceutical products for the treatment of unmet clinical needs,
announced today that an overview of its hCDR1 peptide to treat
patients with systemic lupus erythematosus (SLE) is included in an
article titled, Novel Approaches to the Development of Targeted
Therapeutic Agents for Systemic Lupus Erythematosus. The
article was written by Zev Sthoeger, Amir
Sharabi and Edna Mozes. The
article has been published in the Journal of Autoimmunity.
The article summarizes the information available on the four
most actively studied peptides based on their ability to suppress
lupus manifestations, which includes pCONS, Nucleosomal Peptides,
P140 (LUPUZOR) and hCDR1. The common denominator for these peptides
is being tolerogenic T cell epitopes that down-regulate
specifically lupus associated autoimmune responses.
"We are extremely pleased that Prof. Mozes' review of our hCDR1
peptide for the treatment of lupus was included in the recent
article published in the Journal of Autoimmunity," stated
Josh Levine, Chief Executive Officer
of XTL. "According to the article, out of the four peptides
studied, hCDR1 was identified as one of the synthetic peptides to
demonstrate highly beneficial effects in experimental and human SLE
trials. As a result, hCDR1 was referred to as one of the few
attractive potential candidates for the specific and safe treatment
of lupus patients."
About XTL Biopharmaceuticals Ltd. ("XTL")
XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on
the acquisition, development, and commercialization of
pharmaceutical products for the treatment of unmet clinical needs.
XTL is focused on late stage clinical development of drugs for the
treatment of lupus, multiple myeloma and schizophrenia.
XTL is a public company traded on the Nasdaq Capital Market
(NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL
shares are included in the following indices: Tel-Aviv Biomed,
Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
Cautionary Statement
Some of the statements included
in this press release may be forward-looking statements that
involve a number of risks and uncertainties. For those statements,
we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995.
Investor Contacts:
Jeffrey
Goldberger / Garth
Russell
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1250
Email: jgoldberger@kcsa.com / grussell@kcsa.com
SOURCE XTL Biopharmaceuticals Ltd.